Orbus Therapeutics, established in 2015, is a biopharmaceutical company dedicated to developing innovative therapies for rare diseases. With a focus on rare genetic disorders, Orbus Therapeutics aims to improve the lives of patients with unmet medical needs.
Headquartered in San Francisco, California, the company's pipeline comprises novel therapies targeting various rare diseases, including those affecting the central nervous system and metabolism. Orbus Therapeutics' approach combines deep disease understanding, cutting-edge science, and a patient-centric mindset to drive its mission forward.
Orbus Therapeutics' Pipeline and Therapeutic Areas
Orbus Therapeutics has built a robust pipeline targeting several rare diseases, demonstrating its commitment to addressing unmet needs in this space.
Its lead program, OR-101, is a potential treatment for mucopolysaccharidosis type I (MPS I), a severe lysosomal storage disorder affecting multiple organs and systems. OR-101 is designed to provide systemic enzyme replacement therapy, aiming to address the underlying cause of the disease.
Mucopolysaccharidosis Type I (MPS I)
MPS I, also known as Hurler syndrome, is a progressive and debilitating genetic disorder caused by a deficiency in the enzyme alpha-L-iduronidase. This enzyme is responsible for breaking down complex sugars called glycosaminoglycans (GAGs). In the absence of functional alpha-L-iduronidase, GAGs accumulate in various organs and tissues, leading to severe health problems.
Symptoms of MPS I typically appear in infancy and include coarse facial features, short stature, skeletal abnormalities, organomegaly, and cognitive impairment. OR-101, if approved, would offer a much-needed therapeutic option for patients with this devastating disease.
Other Rare Disease Programs
In addition to OR-101, Orbus Therapeutics is developing therapies for other rare diseases, including Sanfilippo syndrome type A (MPS IIIA) and Krabbe disease. Both of these disorders are caused by genetic defects leading to the accumulation of toxic substances in the body, resulting in progressive neurological deterioration.
The company's approach to these diseases involves developing enzyme replacement therapies and gene therapies, aiming to address the underlying genetic defects and slow or halt disease progression. By targeting these rare diseases, Orbus Therapeutics seeks to make a significant impact on the lives of patients and their families.
Orbus Therapeutics' Collaborations and Partnerships
Orbus Therapeutics has established strategic collaborations and partnerships to advance its pipeline and bring innovative therapies to patients more efficiently.
In 2020, the company entered into a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize OR-101 for the treatment of MPS I. This partnership leverages Takeda's expertise in rare disease drug development and commercialization, further strengthening Orbus Therapeutics' commitment to patients with rare diseases.
Takeda Collaboration
The collaboration with Takeda allows Orbus Therapeutics to accelerate the development of OR-101 while retaining certain rights to the product in specific territories. This partnership also provides Orbus Therapeutics with access to Takeda's global resources and capabilities, enhancing the likelihood of success for OR-101's development and potential commercialization.
Through this collaboration, both companies aim to bring a much-needed therapeutic option to patients with MPS I, ultimately improving their quality of life and addressing the significant unmet medical need in this rare disease area.
As Orbus Therapeutics continues to advance its pipeline and forge strategic partnerships, it remains committed to its mission of developing innovative therapies for rare diseases. By focusing on the unmet needs of patients and their families, the company strives to make a meaningful difference in the lives of those affected by these devastating conditions.